Real-world study of clinical impact of EGFR mutation subtypes on treatment outcomes with tyrosine kinase inhibitors for advanced NSCLC

An Austrian real-world study using a prospectively maintained patient database evaluated clinical impact of EGFR mutation subtypes on treatment outcomes in patients receiving first-line tyrosine kinase inhibitors (TKIs) for advanced non-small cell lung cancer (aNSCLC; stage IIIB or higher). Among 53 patients with an EGFR mutation, median progression-free survival and overall survival were 14.2 months (95% CI 7.4-20.9) and 17.7 months (10.4-24.9), respectively. A total of 36 patients harbored common EGFR mutations (exon 19 deletion or L858R) and exhibited significantly better OS than those with an uncommon EGFR mutation (p<0.005). The longest median OS was seen in patients with exon 19 deletion (32.5 months), followed by patients with L858R (17 months), and patients with uncommon mutations (11.6 months). The authors conclude that these results underscore the prognostic role of distinct EGFR genotypes in aNSCLC.